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Abstract
Transhumanism, designer babies, gene therapy, and super-soldiers are founded upon the same concept—genetic engineering. Clustered Regularly-Interspersed Short Palindromic Repeats (CRISPR) is a natural bacterial immune response
method that takes advantage of gene manipulation to prevent an infection from mobile genetic elements. Since Mojica
et al. (2005) first suggested the relationship between the CRISPR/Cas system and prokaryotic immunity, significant
advancements have been made in understanding the mechanism and subsequent applications of CRISPR. CRISPR,
has three main subtypes based on unique proteins and interference pathways and serves as an accurate and effective
method for gene editing. Its mechanism consists of spacer acquisition, crRNA production, and interference. This highly
dynamic form of genetic modification generates significant CRISPR sequence differences in species that are almost
identical when comparing the rest of their genome. CRISPR/Cas9 demonstrates the simultaneous alteration of multiple
gene loci in individual cells with a high degree of specificity and precision. Duchenne muscular dystrophy (DMD) is a
genetic neuromuscular disorder characterized by progressive muscle loss and eventual death in the late teens to early
twenties. DMD affects calcium homeostasis, vasculature, genetic regulation, muscle movement, glycosylation, tissue
remodeling, and inflammatory response mechanisms. Current treatments include antifibrotic pharmaceuticals, calcium
maintenance, myostatin inhibitors, upregulation of uthrophin, nonsense suppression drugs, vector-mediated gene therapy, and cell transplantation. This review describes the mechanism of CRISPR/Cas9 and its application as a therapeutic
approach to treating Duchenne muscular dystrophy.
Keywords: CRISPR, genomic engineering, Duchenne Muscular Dystrophy, Cas protein, interference mechanism,
PAM recognition
Introduction
DNA sequencing assays are highly efficient and economical and
dramatically increase our understanding of genetic diseases.
Once we identify and comprehend the cause of the disease, the
quandary is to figure how to reverse the mutation and cure it.
The ability to modify genes in mice serves as a crucial function
to model human diseases (Yang et al., 2014). Conventional approaches to study and develop disease models utilize homologous recombination, such as retroviral insertion (Kuehn et al.,
1987), in embryonic stem cells, to knockout the gene of interest
(Thomas and Capecchi, 1987). Genetic variations among embryonic stem cells (Ledermann, 2000) coupled with relatively long
time requirements (Markel et al., 1997) cause significant limitations to this approach (Carbery et al, 2010). Other methods
used in gene editing include zinc-finger nucleases (ZFNs) (Kim
et al., 1996; Geurts et al., 2009) and transcription activator–like
effector nucleases (TALENs) (Nanjidsuren et al., 2016; Tesson
et al., 2011).
Plasmids, bacteriophages, and transposons promote adaptation
and survival by inducing the development of toxic compound
degradation, antibiotic resistance, and other evolutionary advantages (Frost el at., 2005). Among mechanisms used to resist
harmful infections and monitor the entry of genetic material,
bacterial species utilize clustered regularly interspersed short
palindromic repeats (CRISPR) (Labrie et al., 2010). CRISPR, a
defense mechanism ensuring resistance against viral invasion,
is exhibited by an estimated 40 percent of eubacterial and 90
percent archaeal species (Hatoum-Aslan et al., 2011). Kunin et

al. (2007) used PILAR-CR, an algorithm that identifies CRISPR
repeats, and found 561 arrays in 44 percent of the genomes
tested. A population of ~1031 viruses coupled with ~1025/s
rates of infection promoted the evolution of defense pathways
that effectively identify foreign genetic elements and mount a
response to degrade harmful foreign nucleic acids (Hendrix,
2003; Richter et al., 2012). These repeats are ubiquitous in archea and evident in some bacteria (Lillestøl et al., 2006).
While sequencing the Escherichia Coli iap gene in 1987, a researcher identified an “unusual structure” at the 3’ end flanking
the gene, noting five repetitive sequences of 29 nucleotides each
having unique 32 bp spacer segments (Ishino et al., 1987). In
2005, Francisco Mojica was first to suggest a relationship between the CRISPR-Cas system and bacterial immunity. This observation later turned out to be extremely significant, yielding
a dramatic benefit to genetic research. CRISPR, an adaptive
bacterial immunological response mechanism, consists of alternating sequences, one repetitive and the other a segment of a
viral genome or a plasmid sequence. CRISPR utilizes CRISPR
associated (Cas) proteins and small non-coding RNAs for its
function. Abutting each CRISPR loci, CRISPR-associated (CAS)
genes encoding for various enzymatic proteins couple with
CRISPR to form a multitude of different CRISPR/CAS pathways
(Horvath and Barrangou, 2010). Incorporation of phage DNA
into the spacer portion of a CRISPR array in Streptococcus
thermophilus yielded resistance towards viral infection of the
corresponding phage (Barrangou et al., 2007). CRISPR can be
involved in several processes such as; replicon partitioning in
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halo bacteria (Mojica et al., 1995), DNA rearrangements within
a replichore (Deboy et al., 2006), and thermal adaptation in E.
Coli (Riehle et al., 2001). There is a direct correlation between
an increased sensitivity to viral infection and a mutation to the
Cas genes or the spacer sequences of the corresponding virus
(Barrangou et al., 2007; Brouns et al., 2008; Oost et al., 2014).
CRISPR/Cas systems can be used to manipulate genes with substantial precision and accuracy, effectively giving researchers the
ability to develop causal linkages between known mutations and
observed phenotypes (Hsu et al., 2014). This review article will
assess the application of the CRISPR/Cas system as a therapeutic approach to Duchenne muscular dystrophy.

Various Cas genes are found adjacent to all CRISPR arrays with
the exception of Thermoplasma acidophilum (Marraffini and
Sontheimer, 2010a). More than 45 distinct CRISPR associated
protein families have been identified using Hidden Markov models (Haft, 2005). Each subtype of CRISPR is classified based on
associated Cas genes as well as its distinct repeat characteristics
(Gesner, 2011). Three main subtypes are classified based on the
presence of a unique Cas protein: type 1 has Cas3, type 2 has
Cas9, and type 3 has Cas10 (Gleditzsch et al.; 2016, Makarova
et al., 2011a; Richter et al., 2012). A fourth subtype, with its
mechanism and function still uncharacterized, is called CRISPR
type U (Koonin and Makarova, 2013).

Methods

Cas1 and Cas2, a metal-dependent nuclease (Wiedenheft et al.,
2012) and a pH-dependent nuclease (Ka et al., 2014), respectively, are necessary in initiating spacer acquisition by incorporating non-self DNA into the leading end of the CRISPR array
(Mojica et al., 2009). Strains of E. Coli lacking the endogenous
cas genes prevented spacer acquisition from occurring without
affecting further steps in the pathway, outlining their importance
in the first step. Both Cas1 and Cas2 are evident among almost
all CRISPR systems (Makarova et al., 2011b), possess a crucial
role in spacer acquisition (Yosef et al., 2012), and contain highly
conserved motifs. CRISPR type U is the only known form of
CRISPR that does not possess a CRISPR array or Cas1 (Koonin
and Makarova, 2013). These findings outline the importance of
Cas1 and Cas2 in spacer acquisition (Oost et al., 2014). Cas1
and Cas2 form a complex determined by a 2.3Å resolution
crystal structure (Nuñez et al., 2014).

An analysis of scholarly articles with a focus on papers published in peer-reviewed journals with high impact factors were
performed through access to databases of the Touro College
Online Library, Medline, Proquest, NCBI Pubmed, and Google
Scholar. In-print articles were obtained from the Touro College
library in the Avenue J campus. An analysis of both review and
experimental research articles were conducted to delineate
the mechanism and outline recent applications of CRISPR in
a clinical setting. In each database, the search word “CRISPR”
prompted recent publications on that topic. Articles that were
labeled as “similar” to papers published recently were also used.
Proteins associated with CRISPR discussed in this paper were
analyzed using the uniprot database. Original research papers
describing aspects pertaining to the discovery, mechanism, and
applications of CRISPR were found on the webpage of Dr. Lluís
Montoliu’s Lab at Centro Nacional de Biotecnología.

Results
Spacer Acquisition
The genetic interference pathway of the CRISPR/Cas system
is initiated with spacer acquisition upon entry of foreign genetic material (Swarts, 2012; Richter et al., 2012; Marraffini,
2010a). This step is highly dynamic and involves the recognition of foreign DNA by the host as well as its first integration
into the spacer portion of a CRISPR array. Identification of the
foreign genetic element is essential to the CRISPR mechanism.
Proto-spacer adjacent motifs (PAMs) or spacer precursors are
important components of the CRISPR systems. Each CRISPRCAS variant can correspond to a specific spacer precursor or
proto-spacer that will be evident on the foreign DNA particle.
The interference target is determined by a specific short motif
sequence that corresponds to each CRISPR variant. Using the
classification of CRISPR variants determined by Kunin et al.
(2007), a sequence of either two or three nucleotides abutting each proto-spacer was found to be conserved in six main
groups (Mojica et al., 2009). This finding suggests a correlation
between PAMs and each CRISPR-CAS system.
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Both DNA recognition and spacer acquisition will be prevented
if the Cas1-Cas2 complex formation is disrupted by a mutation
(Nuñez et al., 2014). In addition to its role in the CRISPR/Cas
system, Cas1 is believed to be involved DNA repair (Babu et
al., 2010). The recognition of a variant-specific adjacent short
sequence on the foreign DNA particle prompts the incorporation of a spacer precursor. This completes the first step in the
CRISPR defense mechanism (Mojica et al., 2009). Replication
of the inserted repeat begins with the repeat most proximal to
the leader portion of the array (Yosef et al., 2012). The CRISPR
response is amplified through the increase in spacer sequences
corresponding to a specific foreign DNA element (Swarts et
al., 2012).

crRNA Expression
The successful incorporation of a foreign DNA segment into
the spacer region of the CRISPR array and the production of
a multiunit precursor (Koonin, 2006) permits the subsequent
processing of the precursor CRISPR RNA (pre-crRNA) (Oost
et al., 2009; Wiedenheft et al., 2012). The crRNAs specific to
each CRISPR array are integral to the CRISPR pathway. Analysis

CRISPR/Cas9 as a therapeutic approach to Duchenne Muscular Dystrophy

of the CRISPR/Cas system in Escherichia Coli K12 determined
that both the repeats and the spacers within the CRISPR
are transcribed into a long precursor RNA (Marraffini and
Sontheimer, 2010a). The crRNA transcript transcribed from
the CRISPR array requires cleavage prior to activation.
Cas proteins catalyze the conversion of precursor RNAs
(pre-crRNA) into small crRNAs (Gleditzsch et al., 2016;
Marraffini and Sontheimer, 2010b). Eight Cas genes were
identified in this strain: cas123 and casABCDE (Brouns et al.,
2008). After knocking out each individual Cas gene using inframe single-gene deletions (Baba and Mori, 2008), the resulting
transcript determined the position of each gene on the CRISPR
array. Further, the RNA cleavage assays did not require ATP
or divalent metal ions to progress. CasE, an endoribonuclease resembling an RNA-binding protein, fused together with
the maltose binding protein (MalE) in Escherichia coli K12, did
not require any other Cas proteins to cleave the pre-crRNA.
Northern blot analysis determined His20 residue to be essential for catalysis of the pre-crRNA. A casE knockout prevents
the processing of pre-crRNA in Escherichia coli K12 outlining
its importance in the pathway (Brouns et al., 2008). Cascade
(CRISPR-associated complex for antiviral defense), a ribonucleoprotein, is a 405 kDa undecamer made of five different
Cas proteins. Cascade is coupled with a 61 nucleotide crRNA
structure spanning the length of the protein complex that
has a 5’-hydroxyl and 2’,3’-cyclic phosphate termini forming a
seahorse configuration prior to target DNA binding (Jackson et
al., 2014, Jore et al., 2011).
Cas3, essential to all type I CRISPR systems, functions both
as an ATP-dependent type A superfamily 2 helicase and a ssDNA nuclease (Brouns et al., 2008; Gesner, 2011; Huo et al.,
2014; Sinkunas et al., 2011). Cas3, together with the mature
crRNA as a guide and Cascade as a targeting complex, catalyze
the degradation of double stranded DNA elements (Huo et
al., 2014). Brouns et al. exposed Escherichia coli to virulent
Lambda phage in various scenarios to determine the role of
Cascade and Cas3 in resisting phage infection. Two Escherichia
coli strains each contain a CRISPR variant that targets four
important lambda genes: the coding strain produced crRNAs
complimentary to both the coding and non-coding strand of
the four genes, while the template strain produced crRNAs
complementary to the proto-spacer regions. With both
Cascade and Cas3 present, results showed a hundred-fold
and ten million-fold decrease in sensitivity to phage infection
with the coding strain and template strain, respectively. Based
on the aforementioned experiment, the presence of Cascade
and Cas3 is crucial to phage resistance in the CRISPR defense
mechanism (Brouns et al., 2008).

High resolution X-ray structure analyses of Cse3, a component
of Cascade, both before and after cleavage of pre-crRNA, suggests a molecular basis for the mechanism of crRNA recognition
by the Cascade. Three structures of Cse3 bound to different
RNA products all displayed a stem loop complex, suggesting the
involvement of Cse3 in RNA recognition (Gesner et al., 2011).
Processing of pre-crRNA into mature crRNA allows effective
interference by the CRISPR-Cas system.

Interference
The interference stage differs mechanistically among the three
main subdivisions of CRISPR: type I, II, and III. Each subtype accomplishes the same goal of foreign DNA degradation, differing
only in the route of interference. The goal of CRISPR interference is to degrade the foreign genetic elements that correspond
to the acquired spacer sequences in the CRISPR array.
CRISPR type I, evident in both bacteria and archaea, exploits
Cas3 for target degradation. Cascade is the multi-subunit crRNP
(CRISPR ribonucleoprotein) complex that is unique to CRISPR
type I. Different routes, depending on the subtype of CRISPR
type I, can induce a conformational change in the crRNP complex which may cause the recruitment of Cas3 for degradation
(Oost et al., 2014). The interference in CRISPR type I is initiated when the mature crRNA binds to a variant of Cas6, an
endoribonuclease. The variant will depend on the subtype of
CRISPR type 1 (Richter et al., 2012). The crRNA forms a stem
loop within each repeat and bind to the corresponding Cas6
protein. Cas5d, the Cas6 variant of type I-C/Dvulg, processes
the pre-crRNA. Further, Cas5d binds to the mature crRNA
(Nam et al., 2012) and recruits the Cascade which induces a
conformational change in the complex (Oost et al., 2014). In
type I-E, CasA or Cse1, functions to discriminate between self
and foreign DNA through the recognition of a proto-spacer
adjacent motif (PAMs) (Sashital et al., 2012; Westra et al., 2013)
as well as induce interactions between DNA and Cascade (Jore
et al., 2011). The initial interaction with the foreign DNA employed by a short loop on Cse1 recognizes a sequence of seven
nucleotides near the 5’ end in addition to the PAM (Richter et
al., 2012).
The CRISPR Type II system uses trans-activating crRNAs (tracrRNA) in crRNA processing. Strains lacking tracrRNA did not
yield mature crRNA, demonstrating the importance of tracrRNA in crRNA processing. The tracrRNA base pairs with 24
nucleotides (Deltcheva et al., 2011) of the crRNA and recruits
RNase III for cleavage. The fusion of tracrRNA and crRNA to
become a single-guide RNA (sgRNA) can be easily programmed
and is used in the modification of multiple DNA sequences simultaneously (Bolukbasi et al., 2016; Cho et al., 2013; Mali et
al., 2013). The process of cleaving tracrRNA and crRNA also
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requires a Cas protein called Csn1 determined by in-vivo inframe deletions of the gene. The subsequent appearance of
mature crRNA and cleaved tracrRNA after the induced expression of Csn1 further supports the hypothesis that Csn1
is vital to the processing of crRNA and tracrRNA (Deltcheva
et al., 2011). However, Csn1 only serves to stabilize the interaction between pre-crRNA and tracrRNA without a direct
contribution to the catalysis, further emphasizing catalytic role
of RNase III (Fonfara et al., 2013). CRISPR-associated endonuclease Cas9 or Csn1 is Mg2+-dependent and contains two
endonuclease domains. One is a RuvC-like nuclease domain
and the other is a HNH nuclease domain cleaving the target
DNA non-complimentary and complimentary to the crRNA,
respectively (Jinek et al., 2012; Anders et al., 2014; Nishimasu
et al., 2014). Csn1 undergoes a conformational change upon
binding to the tracrRNA and mature crRNA, effectively activating its nuclease activity (Jinek et al., 2014). Although both type I
and type II use PAM recognition to bind to DNA, there are two
technical differences. Firstly, the PAM motif is adjacent to the 5’
end of the crRNA in type I and the 3’ end in type II. Secondly,
the PAM motif of the target DNA in type I is the strand that
directly interacts with the crRNA whereas it is on the displaced
strand in the mechanism of type II. After the ribonucleoprotein
complex is in its active form, the subsequent activation of the
nuclease domains mediates site-specific double stranded breaks
of the foreign DNA via Cas9 (Oost et al., 2014). Sternberg et al.
classified the interaction between the RNA-Cas9 and the target
DNA to be through a three-dimensional collision outlining the
specificity of the CRISPR mechanism (2014).
The crRNP complexes in CRISPR type III are structurally alike
and have similar roles to type I. Type III-A and type III-B are
associated with csm and cmr complexes, respectively. The type
III-A system displays the ability to degrade double-stranded
DNA and single-stranded RNA (Niewoehner and Jinek, 2016),
whereas the type III-B system targets RNA (Hale et al., 2009).
Type III-A, present in staphylococcus epidermidis RP62a, contains nine csm genes (Hatoum-Aslan et al., 2014) and does
not rely on PAM recognition for target degradation (Marraffini
and Sontheimer, 2010b). Instead, the csm complex uses the
csm3 and cas10 subunits to target and degrade single-stranded RNA and double-stranded DNA, respectively. Csm6, a
single-stranded RNA-specific endoribonuclease noted for
its higher eukaryotes and prokaryotes nucleotide-binding
(HEPN) domain, is integral to the function of the csm complex.
Ribonuclease activity was determined to be a common feature
among orthologs of csm6, outlining its importance in the type
III pathway. Although the mechanism of csm6 interference is
currently inconclusive, a notable theory posits that when the
csm complex is unsuccessful in resisting foreign invasion, csm6
somehow activates and targets its own nucleic acids inducing
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apoptosis. Such regulatory methods serve as an important
defense in preventing further infection. Structural analysis of
csm6 in Thermus thermophilus describes multiple binding domains which could indicate that there are ligand-dependent
levels of catalytic activity (Niewoehner and Jinek, 2016). Type
III-B in Thermus thermophilus uses the cmr complex, an 11
subunit protein complex comprised of six distinct proteins
aptly labeled cmr1-6, for RNA degradation. The cmr complex is a Mg2+-dependent endoribonuclease that targets the
RNA strand at multiple sites complementary to the crRNA.
Degradation begins at the 3’ end of the target RNA strand
and cleaves toward the 5’ end with each cleavage separated
by six nucleotides. The distance between two cmr4 subunits
is consistent with the six nucleotide intervals present in the
cleavage mechanism which suggests characterizing cmr4 as a
ribonuclease within the cmr complex (Staals et al., 2013). A
significant distinction in the molecular mechanism of CRISPR
type III is that it relies on Cas10/Csm or Cas10/Cmr complex
for target interference whereas type I and type II require a
recognition sequence (Samai et al., 2015).
It is important to note the ability of the CRISPR/Cas system
to differentiate its own genetic material from foreign nucleic
acids. Without the basic capacity to distinguish self versus nonself, all CRISPR mechanisms would act on their own DNA and
subsequently induce autoimmunity and cell death. The basic
mechanism behind preventing self-degradation relies on a genetic distinction between target and self. Since the sequences
incorporated in the spacers are meant to assist in the recognition of foreign genetic elements, they are the same and should
cause self-interference. However, analysis of the CRISPR array
in Staphylococcus epidermidis yielded dissimilarities between
sequences of target DNA and the CRISPR DNA that are not
in the spacer region. The higher degree of base complementarity between CRISPR DNA and crRNA in regions flanking
the spacer sequences prompts evasion of interference. Adding
fifteen base pairs matching both sides of the spacer’s flanking
sequences onto a target strand showed that interference was
unsuccessful in the plasmid that had the 5’ flanking sequence.
The exact “protective region” was determined to be eight base
pairs flanking the spacer sequence. It is the variable complementarity within sequences abutting the spacer region that
prevents autoimmunity in all CRISPR systems (Marraffini and
Sontheimer, 2010b).

CRISPR/Cas9 Genome Engineering
Jinek et al. (2012) was the first to propose the application of
CRISPR/Cas9 for genomic manipulation. CRISPR/Cas9 is a
form a CRISPR type II and is well understood (Ran et al., 2013).
The purpose of CRISPR/Cas9 is to induce double-stranded
breaks at specific locations within a chromosome. Cong et al.
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(2013) investigated the application of CRISPR/Cas9 in genomic engineering by reconstructing the CRISPR type II locus of
Streptococcus pyogenes SF370 in mammalian cells. A spacer
sequence that resembles a specific portion of the EMX1 gene
adjacent to the proper PAM sequence was designed and then
transfected into 293FT cells along with RNase III, Cas9, tracrRNA, and pre-crRNA. Notably, cleavage activity was prevented
when a base mismatch between the protospacer and the guide
RNA sequence was within eleven nucleotides of the PAM sequence, demonstrating the specificity and accuracy of CRISPR/
Cas9. Results yielded effective cleavage even without the addition of RNase III. This finding outlines three essential components required for this method of genetic engineering; Cas9,
mature crRNA, and trans-activating crRNA.
Cas9 is an endonuclease that requires a Mg cofactor in order to
bind to target DNA (Jinek et al., 2012) and is inhibited by EDTA
(Jiang et al., 2016). The target sequence needs to abut the 5’ end
of a protospacer adjacent motif. Each ortholog of Cas9 requires
a specific PAM sequence. The crRNA contains the twenty nucleotide sequence used to target the gene of interest that leads
to the PAM. Furthermore, the crRNA requires tracrRNA for its
activation into discrete units. When used in genome editing, the
crRNA and tracrRNA are fused together to become a complex commonly called single-guide RNA (sgRNA) or guide RNA
(gRNA) (Ran et al., 2013).
Mali et al. (2013) described how the CRISPR/Cas9 system can
be used to both stimulate homologous recombination and modify a locus. They developed human embryonic kidney HEK 293T
cells that contain a green fluorescent protein (GFP) sequence
with an interruption that prevented functionally fluorescing
GFPs. Two gRNAs were designed to target the region that disrupted florescence. After transfection of a donor to repair the
sequence, Cas9, and a gRNA, flow-activated cell sorting (FACS)
began detecting fluorescing cells at ~20 hours, elucidating the
efficiency of CRISPR/Cas9 in inducing homologous recombination with a repair donor. To demonstrate how CRISPR/Cas9 can
modify genomic loci, Mali et al. (2013) introduced two gRNAs
that would each target nineteen base pairs with one base pair
in-between them and then a double stranded donor sequence
to take its place at the AAVS1 locus. PCR and Sanger sequencing assays confirmed the integration of a foreign sequence in a
genome. These findings demonstrate important applications of
CRISPR in genomic engineering.
Another important application of CRISPR/Cas9 is the single-step induction of mutations in multiple genes. Developing
disease models through targeted deletions and engineering
in multiple chromosomes gives extensive insight into the
formation of various illnesses. Maresch et al. (2016) exploited

electroporation to introduce CRISPR/Cas9 vectors in pancreatic cells and demonstrated optimal results when targeting a “few
hundred cells” in each organ. To investigate pancreatic tumorigenesis, sgRNAs for thirteen tumor-suppressor genes and two
neutral genes were transfected into a mixture of C57BL/6J and
129S mice strains. Magnetic resonance imaging determined the
average time for tumor development to be 10.7 weeks and a
54% tumor incidence at 24 weeks. Next generation sequencing
analysis confirmed a significant number of mutations in the target sites of tumor tissue samples. Furthermore, it did not find
any significant mutation rates in the target sites of the tissue
surrounding the tumors which is explained by the electroporation protocols that target only a few hundred cells in relatively
small area (Maresch et al., 2016). All the aforementioned capabilities of CRISPR/Cas9 amalgamate to produce a highly efficient
and effective method of genomic engineering with a short time
period required to develop disease models. Prospective applications of CRISPR/Cas9 can involve the introduction of targeted
mutations that can prevent the acquisition of diseases such as
Human Immunodeficiency Virus (Lombardo et al, 2007). The future applications of CRISPR engineering are limitless and serve
as an extremely viable option for use as a therapy for Duchenne
Muscular Dystrophy.

Duchenne Muscular Dystrophy
In 1836, Gaetano Conte was the first to describe a case of
Duchenne muscular dystrophy (DMD) (Nigro, 2010), an X
chromosome linked recessive disorder that is classified as
a severe progressive muscle wasting disorder. This neuromuscular disease is caused by a mutation in the DMD gene
that codes for dystrophin (Hoffman et al., 1987), a 427 kDa
rod-shaped cytoskeletal multi-domain protein made of 3,685
amino acids (Koenig et al., 1988) that is expressed in all human
muscle cell types. Dystrophin interacts with dystrobrevin
alpha (Sadoulet-Puccio et al., 1997), alpha-1-syntrophin (Ahn
et al., 1996), and beta-1-syntrophin (Ahn and Kunzel, 1995).
The primary function of dystrophin is to connect a cytoskeleton component, actin, with the extracellular matrix (Norwood
et al., 2000). DMD occurs when mutations affecting the open
reading frame cause premature termination of dystrophin
during translation, resulting in a protein with complete loss of
function (Yiu, 2015). The end result of a deficiency in dystrophin is muscle fiber degeneration and is believed to be secondary to factors such as sarcolemma impairment, structural damage to the cytoskeleton, and an aberrant calcium homeostasis.
Patients with DMD require respiratory, cardiac, orthopaedic,
and nutritional management throughout their lives (Yiu, 2015).
Life expectancy for DMD patients is usually 25 years with the
cause of death commonly being cardiomyopathy or lung issues
(Long et al., 2014).
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Pathophysiology
DMD, being a neuromuscular disorder, detrimentally affects
the body’s mechanical abilities, calcium homeostasis, vasculature, genetic regulation, glycosylation, tissue remodeling, and
inflammatory response mechanisms. The absence of dystrophin or other proteins within the dystrophin associated
complex could significantly decrease normal contractions that
increase tension as the muscle lengthens, or eccentric contractions, thereby damaging the membrane of the muscle fibers. A muscle biopsy will show muscle fiber degeneration or
necrosis. Eventually, the continual attempts to regenerate the
muscle fibers leads to a burnout and begin substituting muscle
for connective and adipose tissues (Deconinck and Dan, 2007).
DMD induces a leak within the calcium channels of the cell.
The lack of dystrophin affects the structure of the membrane
causing compensatory mechanisms that maintain calcium
levels to eventually become ineffective. When there is a prolonged influx of extracellular calcium, proteases are activated,
causing further degradation of the membrane, which leads to
a further increase in intracellular calcium. This glut of calcium
can presumably lead to cellular death.
Neuronal-type NO synthase (nNOS) is normally localized
to the membrane of white muscle fibers and produces nitric
oxide, which is a short-lived highly reactive signaling molecule with important biological functions (Nelson and Cox,
2013). The absence or deficiency of dystrophin causes a
reduction in nNOS activity as well as its delocalization from
the sarcolemma (Brenman et al, 1995; Crosbie et al., 2002).
Dabiré et al. (2012) demonstrated a link between vascular
endothelial dysfunction and the expression of endothelial
and neuronal nitric oxide synthases in DMD patients.
The conversion of mechanical stimuli into electrical or chemical signals is known as mechanotransduction and is involved in
genetic expression and other important physiological processes (Katsumi et al., 2004). Goldspink (1998) demonstrates the
effects of muscle activity on mechanotransduction. The progressive loss of muscle tissue occurs secondary to the lack of
autocrine insulin-like growth factor-1 production, which is used
to repair muscle tissue.

CRISPR/Cas9 Therapy
The human dystrophin gene contains seventy-nine exons and
seventy-eight introns (Kole and Krieg, 2015) with at least seven
promoters. Alternative splicing yields different variants of dystrophin depending on the stage of development and type of
tissue (Im et al., 1996). A spontaneous mdx gene mutation in
a colony of C57BL/10ScSnJ mice resulted in increased serum
levels of specific proteins as well as histological similarities
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compared to that of human muscular dystrophy (Bulfield et al.,
1984). This spontaneous point mutation yielded a stop codon
affecting exon 23 in the dystrophin gene (Sicinski et al., 1989).
Biochemical similarities coupled with cross-breeding analysis
of mutant and normal mice set the precedent to use the mdx
mouse as a model for muscular dystrophy (Bulfield et al., 1984).
Although not entirely equivalent to the human disease, researchers utilize the mdx mouse as the predominant model to
investigate pathogenic mechanisms of DMD (Partridge, 2013).
The primary goal is to cure DMD by correcting any harmful
mutations. Treatments either alleviate the symptoms or aim to
cure the disease itself. Pharmacological approaches improve
muscle function with corticosteroids (Mendell et al., 1989),
maintain calcium homeostasis (Zhao et al., 2012), inhibit the
IKK/NF-κB signaling pathway (Acharyya et al., 2007), reduce inflammation and induce the upregulation of uthrophin as a surrogate to dystrophin (Gordon et al., 2013). Glucocorticoids,
such as prednisone or deflazacort, are beneficial to muscle
function and are the only accepted drug therapy of DMD
(Matthews et al., 2016). Van Deutekom et al. (2001) describes
a form of gene therapy that attempts to correct the reading
frame through the induction of skipping an additional exon.
An exon 45 deletion exhibited in DMD patients causes a stop
codon in exon 46. The open reading frame is restored when
exon 46 is deleted. The resulting protein is still dysfunctional
yet displays a milder form DMD, outlining a method of treating
the disease. Other attempted strategies of treatment include
antifibrotic pharmaceuticals, myostatin inhibitors, nonsense
suppression drugs, vector-mediated gene therapy, and cell
transplantation (Shimizu-Motohashi, 2016).
The aforementioned therapeutic approaches to treat DMD
focus on either reestablishing the expression of or compensating for a deficiency in dystrophin. The efforts to treat DMD are,
in many instances, relatively transient and compensatory without any curative effects. CRISPR/Cas9 is revolutionary for its
attempt to treat the underlying cause of the disease— mutation
or mutations in the dystrophin gene. Long et al. (2014) demonstrated the application of CRISPR/Cas9 to repair the genetic defect in an animal model of DMD. The zygotes of the mdx mouse,
containing a nonsense mutation in exon 23 of the dystrophin
gene (Sicinski et al., 1989), were injected with a 20 nucleotide
single-guide RNA containing a PAM sequence, Cas9, and 90 base
pair single stranded template. This template strand incorporates
four silent mutations as well as a TseI restriction site for data
analysis. After a double-stranded break was induced by Cas9,
the strands were repaired by either homology directed repair
(HDR) or nonhomologous end-joining (NHEJ). The optimized
condition involved injecting the Cas9, sgRNA, and template into
the zygote and then performing re-implantation into a female
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mouse. The offspring of that mouse determined the results of
the experiment. Analysis of eleven repaired mdx progeny revealed adult development of all mice without signs of abnormal
phenotypes. Control groups were used to test for off-target
effects and yielded data consistent with previous genome-wide
studies outlining the specificity of Cas9. Using histological analysis of different muscles, the results of this experiment demonstrated the capability of CRISPR/Cas9 to repair the primary
mutation that causes DMD, thereby preventing the symptoms
associated with the disease. The determined threshold for sufficient repair was 17% which effectively displayed a dystrophin
level comparable to the wild-type mouse.This finding suggests a
mechanism of selective advantage for the repaired skeletal myocytes. Soles and heart tissue immunostaining of a three-week
old mdx repaired mouse of 40% displayed myofibers without
dystrophin while the nine-week old mdx repaired mouse of 41%
did not reveal any myofibers without dystrophin. The dystrophin expression levels between the three and nine week old
mice were insignificant, suggesting a compensatory mechanism
of rescue by the repaired nuclei in a myofiber. Immunostaining
revealed myofibers containing dystrophin secondary to a fusion
between a repaired cell and dystrophic muscle, providing further evidence of a rescue mechanism. Additionally, the serum
creatine kinase levels were inversely related to the percentage
of genomic repair, which is consistent with previous data in this
paper. A higher level of serum creatine kinase signifies muscle
breakdown. The repair of only a percentage of cells can induce
a total rescue, suggesting an unknown mechanism that induces
muscle regeneration in mice treated with CRISPR/Cas9. The
results of this experiment yield a breakthrough in our approach
to cure previously incurable diseases by effectively correcting
the underlying cause of the disease.

Discussion & Conclusion
Analysis of the CRISPR/Cas system, both in terms of its mechanism and bioengineering applications, yields a plethora of data
on various diseases. The short time requirements (Markel et
al., 1997) coupled with the simultaneous manipulation of multiple genes (Bolukbasi et al., 2016) characterizes CRISPR as an
advanced and highly efficient approach to modeling and thus
understanding maladies. Applying a form of CRISPR type II to
induce double stranded breaks provides researchers the ability
to target a portion of DNA with high specificity and then stimulate homologous recombination to modify a specific locus (Mali
et al., 2013). Duchenne muscular dystrophy is a debilitating
neuromuscular disease commonly affecting males and generally
leads to death before the age of 25 (Long et al., 2014). DMD is
a prime example to be used in the application of CRISPR/Cas9
for its well defined mutations that cause the disease. The data
presented in experiments using CRISPR/Cas9 to modify a gene
seem to be consistent and display accuracy and efficiency (Cong

et al., 2013; Mali et al., 2013; Maresch et al., 2016). Based on
current data, CRISPR/Cas9 genomic engineering is a promising
and hopeful route to effectively reverse disease-causing genetic
mutations such as Duchenne muscular dystrophy.
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